Izutsu, Koji http://orcid.org/0000-0001-9129-8057
Yamamoto, Kazuhito
Kato, Koji
Ishikawa, Takayuki
Fukuhara, Noriko
Terui, Yasuhito
Choi, Ilseung
Okubo, Sumiko
Ogawa, Natsumi
Sakai, Mizu
Nishimura, Yasuko
Chyla, Brenda
Sun, Yan
Maruyama, Dai
Funding for this research was provided by:
AbbVie
Article History
Received: 24 March 2023
Revised: 13 July 2023
Accepted: 18 July 2023
First Online: 15 August 2023
Declarations
:
: Koji Izutsu: clinical trial contracts with AbbVie, AstraZeneca, Beigene, Celgene, Chugai Pharmaceutical, Janssen, Novartis and Yakult; and honoraria for lectures from Janssen, AbbVie, Novartis, Celgene, AstraZeneca and Chugai Pharmaceutical. Kazuhito Yamamoto: grants from IQVIA/Genmab, Ono Pharmaceutical, Solasia Pharma, Yakult and Incyte; grants and personal fees from AbbVie, Astra-Zeneca, Bristol-Myers Squibb/Celgene, Chugai Pharmaceutical, Eisai, Meiji Seika Pharma, Nippon Shinyaku, Novartis, Otsuka Pharmaceutical, Takeda and Zenyaku; personal fees from SymBio, HUYA/IQVIA Services Japan, Janssen, Kyowa Kirin, Micron/Daiichi-Sankyo, MSD, Sanofi, Nippon Kayaku and Astellas. Koji Kato: consulting fees from AbbVie, AstraZeneca, Celgene, Chugai Pharmaceutical, Eisai, Janssen, Daiichi Sankyo, Ono Pharmaceutical and Novartis; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Bristol Myers Squibb, Celgene, Dainippon-Sumitomo, Janssen, Kyowa Kirin, MSD, Mundipharma, Ono Pharmaceutical, Takeda, AbbVie, Daiichi Sankyo, Eisai and Chugai Pharmaceutical. Takayuki Ishikawa: grants from AbbVie. Noriko Fukuhara: research grants from AbbVie, Bayer, Chugai Pharmaceutical, Celgene, Genmab and Incyte; and honoraria from AstraZeneca, BMS, Chugai Pharmaceutical, CSL Behring, Dainippon Sumitomo, Eisai, Janssen, Kyowa Kirin, Nippon Shinyaku, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Sanofi, Symbio, Takeda and Zenyaku; and data safety monitoring board for HUYA Japan; and advisory board for AstraZeneca, AbbVie, Eli Lilly, Genmab and Novartis. Yasuhito Terui: consultant/adviser/honoraria from Celgene, Janssen, Eisai, Ono Pharmaceutical, Chugai Pharmaceutical, Symbio and AbbVie; and research grants from AbbVie, Bristol Myers Squibb; and scholarship funds from Ono Pharmaceutical, Eisai and Takeda. IIseung Choi: grants from AbbVie. Sumiko Okubo, Natsumi Ogawa, Mizu Sakai, Yasuko Nishimura, Brenda J Chyla, and Yan Sun: Employees of AbbVie and possible ownership of stocks or options. Dai Maruyama: honoraria from Ono Pharmaceutical, Celgene, Takeda, Janssen, Mundipharma, Eisai, Chugai Pharmaceutical, Kyowa Kirin, MSD, Zenyaku, Bristol Myers Squibb, AstraZeneca, Nippon Shinyaku, AbbVie, Sanofi and SymBio; research grants from Amgen Astellas Biopharma, Celgene, Kyowa Kirin, Novartis, Chugai Pharmaceutical, Ono Pharmaceutical, Takeda, Janssen, Sanofi, MSD, Otsuka Pharmaceutical, Bristol Myers Squibb, Astellas, Eisai and AbbVie; and scholarship funds from Taiho, Chugai Pharmaceutical, Ono Pharmaceutical, Kyowa Kirin and Eisai.